These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 19837126

  • 1. Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL-positive) cells sensitive and resistant to imatinib.
    Mor-Tzuntz R, Uziel O, Shpilberg O, Lahav J, Raanani P, Bakhanashvili M, Rabizadeh E, Zimra Y, Lahav M, Granot G.
    Exp Hematol; 2010 Jan; 38(1):27-37. PubMed ID: 19837126
    [Abstract] [Full Text] [Related]

  • 2. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
    Gatto S, Scappini B, Pham L, Onida F, Milella M, Ball G, Ricci C, Divoky V, Verstovsek S, Kantarjian HM, Keating MJ, Cortes-Franco JE, Beran M.
    Haematologica; 2003 Aug; 88(8):853-63. PubMed ID: 12935973
    [Abstract] [Full Text] [Related]

  • 3. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller-Brüsselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A.
    Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
    [Abstract] [Full Text] [Related]

  • 4. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines.
    Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, Birenbaum M, Bakhanashvili M, Yerushalmi R, Luria D, Lahav M.
    Br J Cancer; 2005 May 23; 92(10):1881-91. PubMed ID: 15870711
    [Abstract] [Full Text] [Related]

  • 5. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
    Morinaga K, Yamauchi T, Kimura S, Maekawa T, Ueda T.
    Int J Cancer; 2008 Jun 01; 122(11):2621-7. PubMed ID: 18338755
    [Abstract] [Full Text] [Related]

  • 6. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
    Liao HF, Su YC, Zheng ZY, Jhih Cai C, Hou MH, Chao KS, Chen YJ.
    Biomed Pharmacother; 2012 Jul 01; 66(5):378-83. PubMed ID: 22397755
    [Abstract] [Full Text] [Related]

  • 7. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M, Nguyen TK, Dent P, Grant S.
    Mol Pharmacol; 2007 Sep 01; 72(3):788-95. PubMed ID: 17595328
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells.
    Tauchi T, Nakajima A, Sashida G, Shimamoto T, Ohyashiki JH, Abe K, Yamamoto K, Ohyashiki K.
    Clin Cancer Res; 2002 Nov 01; 8(11):3341-7. PubMed ID: 12429620
    [Abstract] [Full Text] [Related]

  • 10. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
    Wang W, Zhang J, Li Y, Yang X, He Y, Li T, Ren F, Zhang J, Lin R.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):791-9. PubMed ID: 25449787
    [Abstract] [Full Text] [Related]

  • 11. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
    Okabe S, Tauchi T, Ohyashiki K.
    Clin Cancer Res; 2008 Oct 01; 14(19):6181-6. PubMed ID: 18829496
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells.
    Marley SB, Lewis JL, Schneider H, Rudd CE, Gordon MY.
    Br J Haematol; 2004 May 01; 125(4):500-11. PubMed ID: 15142121
    [Abstract] [Full Text] [Related]

  • 14. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [Abstract] [Full Text] [Related]

  • 15. [Effect of tyrosine kinase inhibitor imatinib mesylate on K562 cell invasion by PTEN pathway].
    Cheng ZY, Liang WT, Yan XY, Wan JS, Bian YS, Bai P, Liang LQ, Jie JQ, Li AM.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Nov 01; 28(11):1129-32. PubMed ID: 23127398
    [Abstract] [Full Text] [Related]

  • 16. Imatinib inhibits the expression of SCO2 and FRATAXIN genes that encode mitochondrial proteins in human Bcr-Abl⁺ leukemia cells.
    Papadopoulou LC, Kyriazou AV, Bonovolias ID, Tsiftsoglou AS.
    Blood Cells Mol Dis; 2014 Nov 01; 53(1-2):84-90. PubMed ID: 24726617
    [Abstract] [Full Text] [Related]

  • 17. Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression.
    Nakanishi T, Shiozawa K, Hassel BA, Ross DD.
    Blood; 2006 Jul 15; 108(2):678-84. PubMed ID: 16543472
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
    Wang XD, Qiu L, Lu RZ, Chen LJ, Zhan ZM, Han BH, Zhang BL, Ma J.
    Zhonghua Yi Xue Za Zhi; 2007 Dec 25; 87(48):3399-405. PubMed ID: 18476538
    [Abstract] [Full Text] [Related]

  • 20. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K.
    Cancer Res; 2002 Oct 15; 62(20):5761-9. PubMed ID: 12384536
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.